{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:24:47Z","timestamp":1777289087927,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T00:00:00Z","timestamp":1537228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T00:00:00Z","timestamp":1537228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"crossref","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate the efficacy and safety of infliximab biosimilar CT-P13 in patients with active Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK received CT-P13 at a starting dose of 5\u00a0mg\/kg at weeks 0, 2, 6, and then every 8 weeks up to week 46. They were followed up until week 54. From week 14 to week 46, patients with inadequate response received increased dose of CT-P13 by 1.5\u00a0mg\/kg. Concomitant prednisolone was allowed\u2009\u2264\u200910\u00a0mg\/day. The primary efficacy end point was the achievement of partial or complete remission at week 30. All patients underwent positron emission tomography\u2013computed tomography (PET\u2013CT) at baseline and week 30. Twelve patients with TAK received CT-P13; one patient with protocol violation was excluded from analysis. Nine (81.8%) patients had taken concomitant prednisolone with median dose of 5.0\u00a0mg\/day. At week 30, three (27.3%) patients achieved complete remission and six (54.5%) patients achieved partial remission. Statistically significant improvements in modified Indian Takayasu Clinical Activity Score (ITAS2010), ITAS-A, and serum levels of erythrocyte sedimentation rate and C-reactive protein were seen at week 30 from baseline. PET parameters were significantly reduced from baseline to week 30, including maximum standardized uptake value, target-to-vein ratio, target-to-liver ratio, and PET Vascular Activity Score. There were no serious adverse events. Treatment with CT-P13 may lead to improvement in clinical, radiographic, and serological activities with lower glucocorticoid requirement in TAK.<\/jats:p><jats:p><jats:bold>Trial registration number<\/jats:bold> NCT02457585.<\/jats:p>","DOI":"10.1007\/s00296-018-4159-1","type":"journal-article","created":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T09:52:21Z","timestamp":1537264341000},"page":"2233-2242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct02457585","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eun Hye","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Jong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You Jung","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Hee","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoong Yong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Chul","family":"Paeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoon Young","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5384-3437","authenticated-orcid":false,"given":"Yeong Wook","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,18]]},"reference":[{"issue":"11","key":"4159_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.7326\/0003-4819-120-11-199406010-00004","volume":"120","author":"GS Kerr","year":"1994","unstructured":"Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS (1994) Takayasu arteritis. Ann Intern Med 120(11):919\u2013929","journal-title":"Ann Intern Med"},{"issue":"1","key":"4159_CR2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0889-857X(21)00371-9","volume":"21","author":"GS Hoffman","year":"1995","unstructured":"Hoffman GS (1995) Treatment of resistant Takayasu\u2019s arteritis. Rheum Dis Clin North Am 21(1):73\u201380","journal-title":"Rheum Dis Clin North Am"},{"issue":"1 Suppl 70","key":"4159_CR3","first-page":"S114","volume":"30","author":"I Kotter","year":"2012","unstructured":"Kotter I, Henes JC, Wagner AD, Loock J, Gross WL (2012) Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 30(1 Suppl 70):S114\u2013S129","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"4159_CR4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/art.1780370420","volume":"37","author":"GS Hoffman","year":"1994","unstructured":"Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS (1994) Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37(4):578\u2013582","journal-title":"Arthritis Rheum"},{"issue":"5 Suppl1","key":"4159_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.semarthrit.2005.01.009","volume":"34","author":"RS Wallis","year":"2005","unstructured":"Wallis RS, Ehlers S (2005) Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34(5 Suppl1):34\u201338. https:\/\/doi.org\/10.1016\/j.semarthrit.2005.01.009","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"4159_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1056\/NEJMra022694","volume":"349","author":"CM Weyand","year":"2003","unstructured":"Weyand CM, Goronzy JJ (2003) Medium- and large-vessel vasculitis. N Engl J Med 349(2):160\u2013169. https:\/\/doi.org\/10.1056\/NEJMra022694","journal-title":"N Engl J Med"},{"issue":"1","key":"4159_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/BOR.0000000000000004","volume":"26","author":"A Clifford","year":"2014","unstructured":"Clifford A, Hoffman GS (2014) Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol 26(1):7\u201315. https:\/\/doi.org\/10.1097\/BOR.0000000000000004","journal-title":"Curr Opin Rheumatol"},{"issue":"2\u20133","key":"4159_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clim.2005.09.010","volume":"118","author":"NK Tripathy","year":"2006","unstructured":"Tripathy NK, Gupta PC, Nityanand S (2006) High TNF-alpha and low IL-2 producing T cells characterize active disease in Takayasu\u2019s arteritis. Clin Immunol 118(2\u20133):154\u2013158. https:\/\/doi.org\/10.1016\/j.clim.2005.09.010","journal-title":"Clin Immunol"},{"issue":"7","key":"4159_CR9","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1002\/art.20300","volume":"50","author":"GS Hoffman","year":"2004","unstructured":"Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50(7):2296\u20132304. https:\/\/doi.org\/10.1002\/art.20300","journal-title":"Arthritis Rheum"},{"issue":"11","key":"4159_CR10","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1136\/ard.2008.093260","volume":"67","author":"ES Molloy","year":"2008","unstructured":"Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS (2008) Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67(11):1567\u20131569. https:\/\/doi.org\/10.1136\/ard.2008.093260","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4159_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2169\/internalmedicine.45.1377","volume":"45","author":"F Tanaka","year":"2006","unstructured":"Tanaka F, Kawakami A, Iwanaga N, Tamai M, Izumi Y, Aratake K, Arima K, Kamachi M, Nakamura H, Huang M, Ida H, Origuchi T, Eguchi K (2006) Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med 45(5):313\u2013316","journal-title":"Intern Med"},{"issue":"6","key":"4159_CR12","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s10067-006-0227-0","volume":"26","author":"ZT Karageorgaki","year":"2007","unstructured":"Karageorgaki ZT, Mavragani CP, Papathanasiou MA, Skopouli FN (2007) Infliximab in Takayasu arteritis: a safe alternative? Clin Rheumatol 26(6):984\u2013987. https:\/\/doi.org\/10.1007\/s10067-006-0227-0","journal-title":"Clin Rheumatol"},{"issue":"5","key":"4159_CR13","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/rheumatology\/ker380","volume":"51","author":"A Mekinian","year":"2012","unstructured":"Mekinian A, Neel A, Sibilia J, Cohen P, Connault J, Lambert M, Federici L, Berthier S, Fiessinger JN, Godeau B, Marie I, Guillevin L, Hamidou M, Fain O, de Medecine I (2012) Club Rhumatismes et Inflammation FVSG, Societe Nationale Francaise. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology 51(5):882\u2013886. https:\/\/doi.org\/10.1093\/rheumatology\/ker380","journal-title":"Rheumatology"},{"issue":"3","key":"4159_CR14","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/art.22404","volume":"56","author":"K Maksimowicz-McKinnon","year":"2007","unstructured":"Maksimowicz-McKinnon K, Clark TM, Hoffman GS (2007) Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 56(3):1000\u20131009. https:\/\/doi.org\/10.1002\/art.22404","journal-title":"Arthritis Rheum"},{"issue":"10","key":"4159_CR15","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/eji.200324390","volume":"33","author":"A Doni","year":"2003","unstructured":"Doni A, Peri G, Chieppa M, Allavena P, Pasqualini F, Vago L, Romani L, Garlanda C, Mantovani A (2003) Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol 33(10):2886\u20132893. https:\/\/doi.org\/10.1002\/eji.200324390","journal-title":"Eur J Immunol"},{"issue":"16","key":"4159_CR16","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/j.jacc.2010.10.058","volume":"57","author":"T Ishihara","year":"2011","unstructured":"Ishihara T, Haraguchi G, Kamiishi T, Tezuka D, Inagaki H, Isobe M (2011) Sensitive assessment of activity of Takayasu\u2019s arteritis by pentraxin3, a new biomarker. J Am Coll Cardiol 57(16):1712\u20131713. https:\/\/doi.org\/10.1016\/j.jacc.2010.10.058","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"4159_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.7326\/0003-4819-155-7-201110040-00005","volume":"155","author":"L Dagna","year":"2011","unstructured":"Dagna L, Salvo F, Tiraboschi M, Bozzolo EP, Franchini S, Doglioni C, Manfredi AA, Baldissera E, Sabbadini MG (2011) Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 155(7):425\u2013433. https:\/\/doi.org\/10.7326\/0003-4819-155-7-201110040-00005","journal-title":"Ann Intern Med"},{"key":"4159_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13027","author":"R Goel","year":"2017","unstructured":"Goel R, Kabeerdoss J, Mohan H, Danda S, Jayaseelan V, Kumar TS, Jude J, Bacon P, Joseph G, Danda D (2017) Soluble-HLA-E: A follow up biomarker in Takayasu arteritis, independent of HLA-E genotype. Int J Rheum Dis. https:\/\/doi.org\/10.1111\/1756-185X.13027","journal-title":"Int J Rheum Dis"},{"issue":"1 Suppl 75","key":"4159_CR19","first-page":"S15","volume":"31","author":"I Karapolat","year":"2013","unstructured":"Karapolat I, Kalfa M, Keser G, Yalcin M, Inal V, Kumanlioglu K, Pirildar T, Aksu K (2013) Comparison of F18-FDG PET\/CT findings with current clinical disease status in patients with Takayasu\u2019s arteritis. Clin Exp Rheumatol 31(1 Suppl 75):S15\u2013S21","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"4159_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jcmg.2012.01.013","volume":"5","author":"D Tezuka","year":"2012","unstructured":"Tezuka D, Haraguchi G, Ishihara T, Ohigashi H, Inagaki H, Suzuki J, Hirao K, Isobe M (2012) Role of FDG PET-CT in Takayasu arteritis: sensitive detection of recurrences. JACC Cardiovasc Imaging 5(4):422\u2013429. https:\/\/doi.org\/10.1016\/j.jcmg.2012.01.013","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"4159_CR21","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/art.1780330811","volume":"33","author":"WP Arend","year":"1990","unstructured":"Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33(8):1129\u20131134","journal-title":"Arthritis Rheum"},{"issue":"3","key":"4159_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4103\/0976-500X.136101","volume":"5","author":"R Serra","year":"2014","unstructured":"Serra R, Grande R, Buffone G, Scarcello E, Tripodi F, Rende P, Gallelli L, de Franciscis S (2014) Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis. J Pharmacol Pharmacother 5(3):193\u2013196. https:\/\/doi.org\/10.4103\/0976-500X.136101","journal-title":"J Pharmacol Pharmacother"},{"issue":"12","key":"4159_CR23","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1007\/s10067-013-2380-6","volume":"32","author":"PI Novikov","year":"2013","unstructured":"Novikov PI, Smitienko IO, Moiseev SV (2013) Tumor necrosis factor alpha inhibitors in patients with Takayasu\u2019s arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature. Clin Rheumatol 32(12):1827\u20131832. https:\/\/doi.org\/10.1007\/s10067-013-2380-6","journal-title":"Clin Rheumatol"},{"issue":"10","key":"4159_CR24","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/rheumatology\/ket128","volume":"52","author":"R Misra","year":"2013","unstructured":"Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM, Jeyaseelan L, Lawrence A, Bacon PA, Indian Rheumatology Vasculitis g (2013) Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology 52(10):1795\u20131801. https:\/\/doi.org\/10.1093\/rheumatology\/ket128","journal-title":"Rheumatology"},{"issue":"6","key":"4159_CR25","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1161\/01.CIR.102.6.636","volume":"102","author":"G Peri","year":"2000","unstructured":"Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, Pizzetti F, Maggioni AP, Moccetti T, Metra M, Cas LD, Ghezzi P, Sipe JD, Re G, Olivetti G, Mantovani A, Latini R (2000) PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 102(6):636\u2013641","journal-title":"Circulation"},{"issue":"7","key":"4159_CR26","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/acr.21636","volume":"64","author":"J Schmidt","year":"2012","unstructured":"Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ (2012) Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res (Hoboken) 64(7):1079\u20131083. https:\/\/doi.org\/10.1002\/acr.21636","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"4159_CR27","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.3899\/jrheum.130154","volume":"40","author":"F Bonilla-Abadia","year":"2013","unstructured":"Bonilla-Abadia F, Canas CA, Echeverri AF (2013) Outcomes of patients with takayasu arteritis treated with infliximab. J Rheumatol 40(11):1930\u20131931. https:\/\/doi.org\/10.3899\/jrheum.130154","journal-title":"J Rheumatol"},{"issue":"5","key":"4159_CR28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10067-010-1658-1","volume":"30","author":"M Osman","year":"2011","unstructured":"Osman M, Aaron S, Noga M, Yacyshyn E (2011) Takayasu\u2019s arteritis progression on anti-TNF biologics: a case series. Clin Rheumatol 30(5):703\u2013706. https:\/\/doi.org\/10.1007\/s10067-010-1658-1","journal-title":"Clin Rheumatol"},{"issue":"7\u20138 Pt 2","key":"4159_CR29","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1016\/j.lpm.2016.11.033","volume":"46","author":"G Keser","year":"2017","unstructured":"Keser G, Aksu K (2017) What is new in management of Takayasu arteritis? Presse Med 46(7\u20138 Pt 2):e229\u2013e235. https:\/\/doi.org\/10.1016\/j.lpm.2016.11.033","journal-title":"Presse Med"},{"issue":"3 Suppl 97","key":"4159_CR30","first-page":"S21","volume":"34","author":"X Kong","year":"2016","unstructured":"Kong X, Sun Y, Ma L, Chen H, Wei L, Wu W, Ji Z, Ma L, Zhang Z, Zhang Z, Zhao Z, Hou J, Dai S, Yang C, Jiang L (2016) The critical role of IL-6 in the pathogenesis of Takayasu arteritis. Clin Exp Rheumatol 34(3 Suppl 97):S21\u2013S27","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"4159_CR31","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/1756-185X.12220","volume":"16","author":"R Goel","year":"2013","unstructured":"Goel R, Danda D, Kumar S, Joseph G (2013) Rapid control of disease activity by tocilizumab in 10 \u2018difficult-to-treat\u2019 cases of Takayasu arteritis. Int J Rheum Dis 16(6):754\u2013761. https:\/\/doi.org\/10.1111\/1756-185X.12220","journal-title":"Int J Rheum Dis"},{"issue":"1 Suppl 70","key":"4159_CR32","first-page":"S98","volume":"30","author":"M Bredemeier","year":"2012","unstructured":"Bredemeier M, Rocha CM, Barbosa MV, Pitrez EH (2012) One-year clinical and radiological evolution of a patient with refractory Takayasu\u2019s arteritis under treatment with tocilizumab. Clin Exp Rheumatol 30(1 Suppl 70):S98\u2013S100","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"4159_CR33","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","volume":"77","author":"Y Nakaoka","year":"2018","unstructured":"Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77(3):348\u2013354. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211878","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4159_CR34","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40037","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, Seo P, Moreland LW, Weisman M, Koening CL, Sreih AG, Spiera R, McAlear CA, Warrington KJ, Pagnoux C, McKinnon K, Forbess LJ, Hoffman GS, Borchin R, Krischer JP, Merkel PA; Vasculitis Clinical Research C (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu Arteritis. Arthritis Rheumatol 69(4):846\u2013853. https:\/\/doi.org\/10.1002\/art.40037.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"4159_CR35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S0002-8703(77)80178-6","volume":"93","author":"E Lupi-Herrera","year":"1977","unstructured":"Lupi-Herrera E, Sanchez-Torres G, Marcushamer J, Mispireta J, Horwitz S, Vela JE (1977) Takayasu\u2019s arteritis. Clinical study of 107 cases. Am Heart J 93(1):94\u2013103","journal-title":"Am Heart J"},{"issue":"1 Suppl 75","key":"4159_CR36","first-page":"S22","volume":"31","author":"Y Cheng","year":"2013","unstructured":"Cheng Y, Lv N, Wang Z, Chen B, Dang A (2013) 18-FDG-PET in assessing disease activity in Takayasu arteritis: a meta-analysis. Clin Exp Rheumatol 31(1 Suppl 75):S22\u2013S27","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"4159_CR37","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jjcc.2016.10.016","volume":"70","author":"N Tamura","year":"2017","unstructured":"Tamura N, Maejima Y, Tezuka D, Takamura C, Yoshikawa S, Ashikaga T, Hirao K, Isobe M (2017) Profiles of serum cytokine levels in Takayasu arteritis patients: potential utility as biomarkers for monitoring disease activity. J Cardiol 70(3):278\u2013285. https:\/\/doi.org\/10.1016\/j.jjcc.2016.10.016","journal-title":"J Cardiol"},{"issue":"2","key":"4159_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3892\/br.2012.42","volume":"1","author":"X Ma","year":"2013","unstructured":"Ma X, Xu S (2013) TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep 1(2):177\u2013184. https:\/\/doi.org\/10.3892\/br.2012.42","journal-title":"Biomed Rep"},{"issue":"2","key":"4159_CR39","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.cyto.2015.04.011","volume":"75","author":"M Takeshita","year":"2015","unstructured":"Takeshita M, Suzuki K, Kikuchi J, Izumi K, Kurasawa T, Yoshimoto K, Amano K, Takeuchi T (2015) Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis. Cytokine 75(2):222\u2013227. https:\/\/doi.org\/10.1016\/j.cyto.2015.04.011","journal-title":"Cytokine"},{"key":"4159_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jaut.2014.01.017","volume":"48\u201349","author":"G Nesher","year":"2014","unstructured":"Nesher G (2014) The diagnosis and classification of giant cell arteritis. J Autoimmun 48\u201349:73\u201375. https:\/\/doi.org\/10.1016\/j.jaut.2014.01.017","journal-title":"J Autoimmun"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-018-4159-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4159-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4159-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T10:13:40Z","timestamp":1628590420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-018-4159-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,18]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4159"],"URL":"https:\/\/doi.org\/10.1007\/s00296-018-4159-1","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,18]]},"assertion":[{"value":"10 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approvement was obtained from Institutional Review Board of Seoul National University Hospital (IRB No: 1312-079-541).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}